Glutamine uptake inhibitors(V-9302), glutamine antimetabolites(L-DON/JHU-083), and glutaminase inhibitors (CB-839) are confirmed to be effective in reshaping glutamine metabolism in immune cells and function as anti-tumor immune microenvironment (Ma et al., 2022). Here, GLS is linked to neoplasm.